AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04658433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 300 mg of omega3-FA
Description: The participant will receive 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA.
Study NCT06053632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-load and high-velocity - lying prone - eccentric hamstring exercise
Description: Low-load and high-velocity - lying prone - eccentric hamstring exercise 3 times per week for 4 weeks.
Study NCT06143514 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06501989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biweekly 5-FLUOROURACIL (5-FU)
Description: 5-FU 2400 mg/m². Infusion for 46 hours. Leucovorin 200 mg/m². Either a vascular endothelial growth factor (VEGF) inhibitor or epidermal growth factor (EGFR) inhibitor or may be added to the regimen at the discretion of the treating physician. Repeat every 2 weeks.
Study NCT06501989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biweekly Modified FOLFOX6
Description: Oxaliplatin 85 mg/m². 5-FU 400 mg/m² on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m² Infusion for 46 hours. Leucovorin 200 mg/m2. Repeat every 2 weeks
Study NCT06501989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biweekly FOLFIRI
Description: Irinotecan 180 mg/m2. 5-FU 400 mg/m2 on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m2 Infusion for 46 hours. Leucovorin 200 mg/m2.~Repeat every 2 weeks.
Study NCT06501989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI
Description: Irinotecan 165 mg/m2. Oxaliplatin 85 mg/m2. 5-FU 2400 mg/m2 Infusion for 46 hours. Repeat every 2 weeks.
Study NCT04895137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6+Bevacizumab+PD-1 monoclonal antibody treatment combinations
Description: mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations in patients with local advanced microsatellite stability colorectal cancer
Study NCT05581121 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment: Control arm
Description: Standard chemo-radiotherapy and brachytherapy according to EMBRACE II and ESGO/ESTRO recommendations.
Study NCT05581121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental arm
Description: Pre-therapeutic para-aortic lymphadenectomy followed by tailored chemo-radiotherapy and brachytherapy.
Study NCT04998214 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: liver function , prothrombin time , INR , US .
Description: analytic
Study NCT04484194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check Yourself - Oncology
Description: A validated AYA-targeted electronic health assessment (eHA) screening tool for use in oncology clinics.
Study NCT05372029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Approach Avoidance Training
Description: AAT condition, participants use a joystick to respond to the color of the border surrounding the stimulus images presented (i.e., pull for green, push for blue). The stimuli used are alcohol-related images and neutral beverage images. To experimentally manipulate automatic action tendencies, a contingency is set between alcohol stimuli and avoidance behaviors
Study NCT05372029 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: In the Sham participants use a joystick to respond to the color of the border surrounding stimulus images presented. There is no contingency between instruction type and pictures (i.e., non-training version of the task)
Study NCT04778046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 129Xe
Description: Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),
Study NCT06105814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid diagnostics
Description: Sputum sampes will in addition to standard diagnostics be investigated using a rapid diagnostic plattform (FilmArray)
Study NCT06376708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: platelet rich fibrin
Description: platelet rich fibrin
Study NCT06376708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polyether ether ketone
Description: Polyether ether ketone
Study NCT06376708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyether ether ketone
Description: Polyether ether ketone
Study NCT05755646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice Plant Intensive Cream plus Standard Care
Description: This group receives a 30-minute nursing consultation on the standard treatment according to the guideline Supportive Therapy for hand-foot syndrome and on the use of the Ice Plant Intensive Cream for the prevention of hand-foot syndrome. The nursing consultation on the standard treatment includes recommended basic measures for the prophylaxis of hand-foot syndrome such as the avoidance of mechanical stress and chemical irritants. In addition, treatment of pre-existing skin conditions is recommended. Furthermore, prophylaxis with urea-containing cream (5-10%) should be applied several times a day.
Study NCT05755646 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: This group receives a 30-minute nursing consultation on the standard treatment according to the guideline Supportive Therapy for hand-foot syndrome. The nursing consultation includes recommended basic measures for the prophylaxis of hand-foot syndrome such as the avoidance of mechanical stress and chemical irritants. In addition, treatment of pre-existing skin conditions is recommended. Furthermore, prophylaxis with urea-containing cream (5-10%) should be applied several times a day.
Study NCT04824937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaglenastat
Description: Capsule, taken by mouth
Study NCT04824937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Capsule, taken by mouth
Study NCT05111574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection
Study NCT05111574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection
Study NCT05111574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT05111574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT05111574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT05111574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05111574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04985227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home weight monitoring
Description: Parents will be provided with weighing scales to weigh their infant at home and plug in the weight in the patient portal for review by their primary care provider.
Study NCT06358118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buyuan Zhixiao Formula
Description: Buyuan Zhixiao Formula
Study NCT06358118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains 10% of the active ingredients of the Chinese medicine group
Study NCT04142671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualised gait modification intervention
Description: An individualised gait modification intervention to reduce knee joint loading. Knee joint loading will be presented in real-time during treadmill walking. A 10% reduction of each patients baseline knee loading will be used as a target threshold along with visualisation of the history of 5 previous steps. Patients are encouraged to determine their own gait modification strategy that is most efficient for them. Previous examples of gait modifications that mechanically reduce knee loading will be presented to them.
Study NCT05111574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT05111574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT05111574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05111574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05111574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT05111574 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV
Study NCT05111574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT05111574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT05111574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT04547140 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liquid Alpha1-Proteinase Inhibitor (Human)
Description: Intravenous infusion 120 mg/kg
Study NCT05759299 — intervention group
Intervention type: PROCEDURE
Intervention: Advanced airway management
Description: Advanced airway management with either tracheal intubation or supraglottic airways performed after induction with hypnotic and/or opioid drugs
Study NCT05095376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Given PO
Study NCT05095376 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Beam Radiation Therapy
Description: Undergo radiation therapy
Study NCT05095376 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon Beam Radiation Therapy
Description: Undergo radiation therapy
Study NCT04547140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion
Study NCT04547140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: SMT
Study NCT04547140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Medical Treatment
Description: SMT
Study NCT05095376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05095376 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05095376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05095376 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05095376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT05095376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Given PO
Study NCT04868448 — intervention group
Intervention type: BIOLOGICAL
Intervention: Covid-19 vaccines
Description: Observation of individuals who received one or more doses of covid-19 vaccines.
Study NCT05108623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agenT-797
Description: agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
Study NCT05108623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Approved ICIs
Description: Nivolumab and pembrolizumab
Study NCT06350201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavior therapy
Description: Problem-solving therapy-based holistic emotion management interventions matched to individual symptoms
Study NCT06350201 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: Routine psychological care and guidance on mood management
Study NCT03968913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra injection
Description: anakinra 150mg in 5milliliters of sterile saline will be injected into the knee joint
Study NCT03968913 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sterile saline injection
Description: 5 milliliters of sterile saline will be injected into the knee joint
Study NCT05532384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early resumption of oral intake
Description: as above
Study NCT05532384 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Late resumption of oral intake
Description: as above
Study NCT05739071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: JING SI HERBAL TEA
Description: JING SI HERBAL TEA is a food, contain with herbal extracts
Study NCT05739071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will have the same appearance as JING SI HERBAL TEA
Study NCT06452602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction immunochemotherapy followed by Adebrelimab plus concurrent chemoradiotherapy
Description: Induction immunochemotherapy:~Nab-paclitaxel：220mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Adebrelimab：1200mg, IV，d1, d22.~Evaluation of the Curative Effect：CR+PR~Adebrelimab plus concurrent chemoradiotherapy:~Adebrelimab：1200mg, IV，q3w, until PD; Nab-paclitaxel：175mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Radiotherapy：50.4Gy/1.8Gy/28f.
Study NCT06452602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction immunochemotherapy followed by concurrent chemoradiotherapy
Description: Induction immunochemotherapy:~Nab-paclitaxel：220mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Adebrelimab：1200mg, IV，d1, d22.~Evaluation of the Curative Effect：SD+PD~Concurrent chemoradiotherapy:~Oxaliplatin：85 mg/m2，IV，d1，d15，d29; Leucovorin：400mg/m2，IV，d1，d15，d29; 5-FU：400mg/m2，IV，d1，d15，d29; 5-FU：1600mg/m2，CIV48h，d1，d15，d29; Radiotherapy：PTV/PGTV:50.4Gy/59.92Gy/28f.
Study NCT05646732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS-fMRI
Description: Participants will undergo simultaneous TMS and fMRI
Study NCT04153955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobilization
Description: Any movement out of bed
Study NCT04153955 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization
Description: Any movement out of bed
Study NCT04742504 — intervention group
Intervention type: BIOLOGICAL
Intervention: BENRALIZUMAB
Description: The decision of the patients treatment with benralizumab (Fasenra®, Astra Zeneca) included in the study will not come in any case influenced by their participation in the study but will be made in accordance with the clinical criteria established by the Asthma Multidisciplinary Unit (UMA).
Study NCT05457179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Park-based physical activity
Description: The experimental arm will optimize a 12-week intervention 3 days/wk, last approximately 60 minutes, and consist of 10 minutes of warm up, 15 minutes of simple strength training activities, 25 minutes of moderate to vigorous aerobic activities (e.g., walking), and 10 minutes of cool down. The eight full-body strength training exercises will use body weight and/or elastic bands and will include a circuit of chest press, seated row, squat, shoulder press, biceps curl, triceps extension, calf raise, and reverse crunch. Sessions will include education and skill building activities focused on Social Cognitive Theory mechanisms of change including self-efficacy, goal setting, and social support. Under the guidance of trained research staff, certified peer specialists who have experience working with peer groups, will be selected to help deliver the intervention.
Study NCT05457179 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: The active control group will receive information about the importance of park-based PA and a map of local park locations but will not participate in structured park-based PA sessions. Participants in the control group will be invited to participate in park PA sessions after they have completed posttest.
Study NCT04655508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide
Description: For children between 6 to 11 years (\< 12 years): 50 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 50/25) :two puffs twice a day from randomisation during 6 months using inhalation chamber~- For children between 12 to 17 years (> or = 12 years) : 125 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 125/25): two puffs twice a day from randomisation during 6 months using inhalation chamber
Study NCT04655508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For children between 6 to 11 years (\< 12 years): placebo of SERETIDE® 50/25 :two puffs twice a day from randomisation during 6 months using inhalation chamber For children between 12 to 17 years (> or = 12 years) : placebo of SERETIDE® 125/25: two puffs twice a day from randomisation during 6 months using inhalation chamber
Study NCT05916807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization Exercises
Description: It consists of 26 patients who will receive stabilization exercises which will be divided in three components in lying posture, sitting, standing, rolling and kneeling positions to treat posterior, inferior muscles of scapula for 35-45 min for 3 days a week for 4 weeks.
Study NCT05916807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posture Training
Description: It consists of 26 patients who will receive postural training and breast-feeding patterns for the mother and child for 35-45 min in 3 days a week for 4 weeks.
Study NCT05276583 — intervention group
Intervention type: BEHAVIORAL
Intervention: Motivated Learning Task
Description: The Motivated Learning Task is split into two parts, the learning phase, and the test phase. During the learning phase participants are presented with 72 landscape images (targets) which they must memorise. Each image which participants are shown is associated with a reward amount. During the test phase participants are shown the 72 images they saw during the learning phase, known as targets, intermixed with 72 new images they did not see during the learning phase, known as lures. Participants must decide whether the image is old (i.e., they saw it during the learning phase) or new (i.e. they did not see it during the learning phase). After they have made their old/new decision, participants rate their confidence in their decision on a 3-point scale (i.e., guess, sure, very sure).
Study NCT06525051 — intervention group
Intervention type: DRUG
Intervention: Tiotropium
Description: Tiotropium is a long-acting anticholinergic agent and has a bronchodilator effect. According to the COPD Gold 2024 guideline, it is one of the long-acting bronchodilator drugs used as the first choice in the treatment of group A COPD patients.
Study NCT04058457 — intervention group
Intervention type: DEVICE
Intervention: DBS
Description: Patients are tested pre-operatively and the post-operatively with their implanted neurostimulators ON and OFF. DBS implantation itself is part of routine care, and not part of the study.
Study NCT05239728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Three 40 mg tablets given as a single oral 120 mg dose.
Study NCT05239728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg via IV infusion
Study NCT05239728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet
Study NCT04547946 — intervention group
Intervention type: DRUG
Intervention: dabrafenib + trametinib
Description: There was no treatment allocation. Patients administered adjuvant treatment with combination therapy of Dabrafenib (Tafinlar®) and Trametinib (Mekinist®) by prescription that had started before inclusion of the patient into the study could be enrolled.
Study NCT05970562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambulatory Voice Monitoring with Biofeedback (AVM-B)
Description: AVM-B is software on the Voice Health Monitor that uses a neck-placed accelerometer to sense neck skin vibrations during voicing in daily life. The AVM-B consists of cues every time the patient exceeds a subject-specific threshold, \[100% frequency AVM-B\] and/or summary statistics every 2 minutes of voicing \[Summary AVM-B\].
Study NCT05970562 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conversation Training Therapy
Description: CTT is a 4-week (1 45-minute session per week) evidence-based voice therapy for patients with VH, developed primarily to maximize the amount and speed of generalization outside the therapy session. It consists of 3 required targets: Decreased overall auditory-perceptual voice severity, improved discrimination between baseline and improved voicing, and adherence to CTT recommendations in daily life. The three optional targets are decreased overall auditory-perceptual severity across an increased pitch range, loudness range, and decreased rate of speech. All voice-related targets are modified through practicing voicing with increased forward resonance and mean airflow in spontaneous speech/conversation.